Managing Lifecycles Amid Stifling Competition
Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.
You may also be interested in...
An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.